Bendamustine and rituximab as induction therapy in both transplant-eligible and -ineligible patients with mantle cell lymphoma

Rituximab-containing chemotherapy regimens constitute standard first-line therapy for mantle cell lymphoma (MCL). Since June 2013, 190 patients ≥18 years of age with MCL in British Columbia have been treated with bendamustine and rituximab (BR). The overall response rate to BR was 88% (54% complete...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Blood Adv
Asıl Yazarlar: Villa, Diego, Sehn, Laurie H., Savage, Kerry J., Toze, Cynthia L., Song, Kevin, den Brok, Wendie D., Freeman, Ciara L., Scott, David W., Gerrie, Alina S.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Hematology 2020
Konular:
Lymphoid Neoplasia
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7422137/
https://ncbi.nlm.nih.gov/pubmed/32735654
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020002068
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller